| scholarly article | Q13442814 |
| P50 | author | Ariel Graff-Guerrero | Q47527099 |
| Gary Remington | Q80160585 | ||
| P2093 | author name string | Masaru Mimura | |
| Takayuki Abe | |||
| Hiroyuki Uchida | |||
| Koichiro Watanabe | |||
| Takefumi Suzuki | |||
| Robert R Bies | |||
| Hiroyoshi Takeuchi | |||
| P2860 | cites work | The positive and negative syndrome scale (PANSS) for schizophrenia | Q28301751 |
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia | Q33235110 | ||
| Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. | Q34145251 | ||
| Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy | Q34147129 | ||
| The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity | Q34482688 | ||
| Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder | Q34603527 | ||
| Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis | Q35065378 | ||
| Less unique variance than meets the eye: overlap among traditional neuropsychological dimensions in schizophrenia | Q37076356 | ||
| Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis | Q37892853 | ||
| Cognitive impairment in schizophrenia | Q38048643 | ||
| Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial | Q43128782 | ||
| Processing speed deficits in schizophrenia: reexamining the evidence | Q44310613 | ||
| Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study | Q46543106 | ||
| Association of anticholinergic load with impairment of complex attention and memory in schizophrenia | Q48102632 | ||
| Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. | Q51185833 | ||
| The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. | Q51390594 | ||
| [The Japanese version of RBANS (Repeatable Battery for the Assessment of Neuropsychological Status)]. | Q52011228 | ||
| Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia | Q57616603 | ||
| A depression rating scale for schizophrenics | Q68663014 | ||
| Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates | Q70267459 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| risperidone | Q412443 | ||
| P304 | page(s) | 993-998 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study | |
| P478 | volume | 39 |
| Q35965634 | A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder |
| Q38233228 | A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy |
| Q60046495 | Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia |
| Q54748022 | Benefit of extending the dosing interval of long-acting antipsychotic injections in elderly schizophrenics with cognitive dysfunction. |
| Q54741377 | Benefit of extending the dosing interval of long-acting antipsychotic injections on schizophrenics with extrapyramidal symptoms. |
| Q37729158 | Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia. |
| Q47913720 | Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia |
| Q36033253 | Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. |
| Q90605703 | Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial |
| Q46700302 | Cross-site strain comparison of pharmacological deficits in the touchscreen visual discrimination test |
| Q57191834 | Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes |
| Q52641630 | Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study. |
| Q38211233 | Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies |
| Q91466571 | Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials |
| Q89729917 | Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★ |
| Q50560110 | Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction. |
| Q47556225 | Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis? |
| Q30835228 | Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort |
| Q26770497 | Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review |
| Q50645808 | Neurodevelopmental origin of cognitive impairment in schizophrenia. |
| Q33857710 | Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies |
| Q47141676 | One patient with schizophrenia showed reduced drug-induced extrapyramidal symptoms as a result of an alternative regimen of treatment with paliperidone 3 and 6 mg every other day. |
| Q64068715 | Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders |
| Q39633628 | Pharmacokinetic patterns of risperidone-associated adverse drug reactions |
| Q54920392 | Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota. |
| Q37124952 | Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study |
| Q33878816 | Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review |
| Q90745559 | The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical Applications |
| Q55216457 | Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. |
| Q55023835 | What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? |
| Q57178733 | [Schizophrenia and bipolar disorder : Treatment of cognitive impairments] |
Search more.